

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person* <u>EVNIN LUKE</u> (Last) (First) (Middle) <u>C/O MPM BIOIMPACT LLC</u> <u>399 BOYLSTON STREET, SUITE 1100</u> (Street) <u>BOSTON MA 02116</u> (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>Werewolf Therapeutics, Inc. [HOWL]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) <u>05/27/2026</u>	
	4. If Amendment, Date of Original Filed (Month/Day/Year)	

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	05/27/2026		s ⁽¹⁾		80,852 ⁽²⁾	D	\$0.48 ⁽³⁾	682,833	I	See Footnotes ⁽⁴⁾⁽⁵⁾
Common Stock	05/28/2026		s ⁽¹⁾		27,698 ⁽⁶⁾	D	\$0.46 ⁽⁷⁾	655,135	I	See Footnotes ⁽⁴⁾⁽⁸⁾
Common Stock	05/29/2026		s ⁽¹⁾		32,556 ⁽⁹⁾	D	\$0.45 ⁽¹⁰⁾	622,579	I	See Footnotes ⁽⁴⁾⁽¹¹⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					(A)	(D)	Date Exercisable	Expiration Date					
					Code	V			Title	Amount or Number of Shares			

Explanation of Responses:

- Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated March 26, 2026.
- The shares were sold as follows: 8,663 by MPM Asset Management LLC ("AM LLC"), 54,692 by MPM BioVentures 2014, L.P. ("BV 2014"), 3,648 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 1,883 by MPM Asset Management Investors BV2014 LLC ("AM BV2014") and 11,966 by MPM Oncology Innovations Fund, L.P. ("MPM OIF").
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$0.46 to \$0.49705 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
- The shares are held as follows: 73,157 by AM LLC, 461,914 by BV 2014, 30,807 by BV 2014(B), 15,896 by AM BV2014 and 101,059 by MPM OIF.
- The shares were sold as follows: 2,968 by AM LLC, 18,736 by BV 2014, 1,250 by BV 2014(B), 645 by AM BV2014 and 4,099 by MPM OIF.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$0.455 to \$0.4858 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The shares are held as follows: 70,189 by AM LLC, 443,178 by BV 2014, 29,557 by BV 2014(B), 15,251 by AM BV2014 and 96,960 by MPM OIF.
- The shares were sold as follows: 3,488 by AM LLC, 22,023 by BV 2014, 1,469 by BV 2014(B), 758 by AM BV2014 and 4,818 by MPM OIF.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$0.44 to \$0.4557 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The shares are held as follows: 66,701 by AM LLC, 421,155 by BV 2014, 28,088 by BV 2014(B), 14,493 by AM BV2014 and 92,142 by MPM OIF.

/s/ Luke Evnin

05/29/2026

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

**** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).**

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.